Targeting cancer with power and precision

Eleven Biotherapeutics, Inc. (NASDQ: EBIO) is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the company's targeted protein therapeutics (TPTs) platform. The company believes its TPTs can potentially offer significant advantages in treating cancer versus existing antibody drug conjugate technologies. Eleven’s approach to drug design creates TPTs that it believes facilitate effective tumor targeting with cancer cell-killing properties unique to protein payloads versus small molecules. The ability of TPTs cancer cell-killing properties to promote an anti-tumor immune response suggest that TPTs will potentially combine well with immune oncology drugs.


In September of 2016, Eleven announced the acquisition of Viventia Bio Inc. Eleven’s pipeline now includes Viventia’s lead product candidates Vicinium and Proxinium.


Year Invested: 2010
Location: Cambridge, Mass.

Recent News

June 12, 2017
Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference

June 6, 2017
Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer

June 1, 2017
Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Viciniumâ„¢ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data

Read More News

Associated Team Members

Mark Levin

Cary Pfeffer, M.D.

Abbie Celniker, Ph.D.